CIK 0000711377
NEOG NEOGEN CORP
Insider trading from SEC Form 4. Last filing 25 h ago.
Last 90 days
Net insider value
+$6,035
more bought than sold
Buys
1
$6,035 by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at NEOGEN CORP, scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 31Weak | buy | Nassif Mikheal CEO | $6,035 | 505 | +47% | - | |
| 40Moderate | buy | ADENT JOHN EDWARD CEO | $200k | 14,500 | +7% | - |
Transactions
The last 22 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | Nassif Mikheal CEO | POpen-market purchase Common Stockindirect: By son | +505 | $11.95 | $6,035 | 1,579 | 25 h ago |
| Nov 1, 2024 | Bernard Thierry director | AGrant or award Restricted Stock Units | +5,620 | $14.44 | $81k | 5,620 | Nov 5, 2024 |
| Nov 1, 2024 | Bernard Thierry director | AGrant or award Common Stock (Right to Buy)derivative | +17,207 | $0.00 | $0 | 17,207 | Nov 5, 2024 |
| Oct 28, 2024 | ADENT JOHN EDWARD CEO | MOption exercise Common Stock | +38,760 | $13.81 | $535k | 257,409 | Oct 29, 2024 |
| Oct 28, 2024 | CAPELLO JEFFREY D director | MOption exercise Common Stock | +1,776 | $13.81 | $25k | 5,917 | Oct 29, 2024 |
| Oct 28, 2024 | BOEHM WILLIAM T director | MOption exercise Common Stock | +1,776 | $13.81 | $25k | 31,214 | Oct 29, 2024 |
| Oct 28, 2024 | BOREL JAMES C director | MOption exercise Common Stock | +1,776 | $13.81 | $25k | 25,474 | Oct 29, 2024 |
| Oct 28, 2024 | CAPELLO JEFFREY D director | MOption exercise Restricted Stock Unitsderivative | -1,776 | $13.81 | $25k | 3,552 | Oct 29, 2024 |
| Oct 28, 2024 | BOREL JAMES C director | MOption exercise Restricted Stock Unitsderivative | -1,776 | $13.81 | $25k | 3,552 | Oct 29, 2024 |
| Oct 28, 2024 | BOEHM WILLIAM T director | MOption exercise Restricted Stock Unitsderivative | -1,776 | $13.81 | $25k | 3,552 | Oct 29, 2024 |
| Oct 28, 2024 | ADENT JOHN EDWARD CEO | FTax withholding Common Stock | -11,280 | $13.81 | $156k | 246,129 | Oct 29, 2024 |
| Oct 28, 2024 | ADENT JOHN EDWARD CEO | MOption exercise Restricted Stock Unitsderivative | -38,760 | $13.81 | $535k | 77,520 | Oct 29, 2024 |
| Oct 24, 2024 | BOEHM WILLIAM T director | AGrant or award Restricted Stock Units | +6,075 | $13.58 | $82k | 41,137 | Oct 28, 2024 |
| Oct 24, 2024 | BOREL JAMES C director | AGrant or award Restricted Stock Units | +6,075 | $13.58 | $82k | 35,397 | Oct 28, 2024 |
| Oct 24, 2024 | CAPELLO JEFFREY D director | AGrant or award Restricted Stock Units | +6,075 | $13.58 | $82k | 15,840 | Oct 28, 2024 |
| Oct 24, 2024 | BOEHM WILLIAM T director | AGrant or award Common Stock (Right to Buy)derivative | +18,653 | $0.00 | $0 | 18,653 | Oct 28, 2024 |
| Oct 24, 2024 | BOREL JAMES C director | AGrant or award Common Stock (Right to Buy)derivative | +18,653 | $0.00 | $0 | 18,653 | Oct 28, 2024 |
| Oct 24, 2024 | CAPELLO JEFFREY D director | AGrant or award Common Stock (Right to Buy)derivative | +18,653 | $0.00 | $0 | 18,653 | Oct 28, 2024 |
| Oct 14, 2024 | ADENT JOHN EDWARD CEO | MOption exercise Common Stock | +3,064 | $14.43 | $44k | 219,541 | Oct 15, 2024 |
| Oct 11, 2024 | ADENT JOHN EDWARD CEO | POpen-market purchase Common Stock | +14,500 | $13.80 | $200k | 216,477 | Oct 15, 2024 |
| Oct 14, 2024 | ADENT JOHN EDWARD CEO | FTax withholding Common Stock | -892 | $14.43 | $13k | 218,649 | Oct 15, 2024 |
| Oct 14, 2024 | ADENT JOHN EDWARD CEO | MOption exercise Restricted Stock Unitsderivative | -3,064 | $14.43 | $44k | 6,127 | Oct 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- ADENT JOHN EDWARDCEO
- BOEHM WILLIAM Tdirector
- BOREL JAMES Cdirector
- Bernard Thierrydirector
- CAPELLO JEFFREY Ddirector
- Nassif MikhealCEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.